Clinical Challenges: Expanding IO Options in TNBC

(MedPage Today) -- In the 21 months since the FDA granted accelerated approval to atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) for locally advanced or metastatic PD-L1 positive triple-negative breast cancer (TNBC), Halle Moore, MD, of...